Cervical cancer control, priorities and new directions
Version of Record online: 24 OCT 2003
Copyright © 2003 Wiley-Liss, Inc.
International Journal of Cancer
Volume 108, Issue 3, pages 329–333, 20 January 2004
How to Cite
Monsonego, J., Bosch, F. X., Coursaget, P., Cox, J. T., Franco, E., Frazer, I., Sankaranarayanan, R., Schiller, J., Singer, A., Wright, T., Kinney, W., Meijer, C. and Linder, J. (2004), Cervical cancer control, priorities and new directions. Int. J. Cancer, 108: 329–333. doi: 10.1002/ijc.11530
- Issue online: 21 NOV 2003
- Version of Record online: 24 OCT 2003
- Manuscript Accepted: 1 AUG 2003
- Manuscript Received: 28 JUL 2003
- cervical neoplasia;
- human papillomavirus;
- HPV vaccine
Cervical cancer is caused by infection with a range of high risk “oncogenic” human papillomavirus (HPV) types, and it is now accepted that >99% of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than 1 in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer.1
The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference. © 2003 Wiley-Liss, Inc.